Mount Yale Investment Advisors LLC Makes New $290,000 Investment in Agilent Technologies, Inc. (NYSE:A)

Mount Yale Investment Advisors LLC acquired a new position in Agilent Technologies, Inc. (NYSE:A) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 1,993 shares of the medical research company’s stock, valued at approximately $290,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Ballentine Partners LLC lifted its stake in shares of Agilent Technologies by 2.5% in the 1st quarter. Ballentine Partners LLC now owns 2,963 shares of the medical research company’s stock valued at $431,000 after purchasing an additional 73 shares during the period. Haverford Trust Co raised its stake in Agilent Technologies by 1.7% during the first quarter. Haverford Trust Co now owns 4,423 shares of the medical research company’s stock valued at $644,000 after buying an additional 74 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in Agilent Technologies by 3.2% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 2,421 shares of the medical research company’s stock valued at $337,000 after buying an additional 75 shares during the last quarter. Carmel Capital Partners LLC raised its stake in Agilent Technologies by 1.2% during the fourth quarter. Carmel Capital Partners LLC now owns 6,709 shares of the medical research company’s stock valued at $933,000 after buying an additional 78 shares during the last quarter. Finally, Monumental Financial Group Inc. raised its stake in Agilent Technologies by 0.9% during the fourth quarter. Monumental Financial Group Inc. now owns 9,493 shares of the medical research company’s stock valued at $1,320,000 after buying an additional 89 shares during the last quarter.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Evercore ISI lifted their target price on Agilent Technologies from $126.00 to $130.00 and gave the stock an “in-line” rating in a report on Tuesday, July 2nd. UBS Group reduced their target price on Agilent Technologies from $155.00 to $141.00 and set a “neutral” rating for the company in a report on Thursday, May 30th. Wolfe Research lowered Agilent Technologies from an “outperform” rating to a “peer perform” rating in a report on Thursday, June 27th. TD Cowen reissued a “buy” rating and issued a $153.00 target price on shares of Agilent Technologies in a report on Monday. Finally, Bank of America lifted their price objective on Agilent Technologies from $134.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, June 25th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, Agilent Technologies has an average rating of “Moderate Buy” and an average price target of $138.06.

Insider Buying and Selling

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $130.00, for a total transaction of $254,540.00. Following the completion of the sale, the chief executive officer now owns 25,185 shares in the company, valued at $3,274,050. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $130.00, for a total transaction of $254,540.00. Following the completion of the sale, the chief executive officer now owns 25,185 shares in the company, valued at approximately $3,274,050. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Dominique Grau sold 15,000 shares of the stock in a transaction on Monday, June 10th. The shares were sold at an average price of $133.28, for a total value of $1,999,200.00. Following the sale, the senior vice president now owns 49,486 shares of the company’s stock, valued at approximately $6,595,494.08. The disclosure for this sale can be found here.

Agilent Technologies Trading Up 0.0 %

NYSE A traded up $0.06 during trading hours on Monday, hitting $137.38. 1,222,648 shares of the company were exchanged, compared to its average volume of 1,772,071. The stock has a 50-day moving average price of $134.57 and a 200 day moving average price of $137.63. The company has a quick ratio of 1.64, a current ratio of 2.15 and a debt-to-equity ratio of 0.34. Agilent Technologies, Inc. has a 52 week low of $96.80 and a 52 week high of $155.35. The stock has a market cap of $40.08 billion, a PE ratio of 32.48, a price-to-earnings-growth ratio of 4.67 and a beta of 1.05.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, May 29th. The medical research company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.03. The firm had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Agilent Technologies had a return on equity of 26.25% and a net margin of 18.84%. The company’s quarterly revenue was down 8.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.27 earnings per share. Analysts forecast that Agilent Technologies, Inc. will post 5.24 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 24th. Investors of record on Tuesday, July 2nd were paid a $0.236 dividend. The ex-dividend date of this dividend was Tuesday, July 2nd. This represents a $0.94 annualized dividend and a yield of 0.69%. Agilent Technologies’s dividend payout ratio (DPR) is currently 22.22%.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.